Skip to main content

Hemex banks 7.1 million Swiss francs

| News

Hemex banks 7.1 million Swiss francs

29.11.2021

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in startups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

Hemex has successfully closed a second tranche of its Series C financing round, further details of which can be found in a press release. In so doing, the company for clinical contract research and investments in startups active in the healthcare industry has so far raised a total of 7.1 million Swiss francs in the year to date.

Hemex, a partner of the investment and innovation promotion agency Basel Area Business & Innovation, intends to use this fresh capital injection to finance initial investments in early-phase startups active in the field of life sciences. Moreover, the company, which is based in Liestal in the canton of Basel-Landschaft, will seek to recruit new team members for clinical activities, quality assurance and regulatory matters.

The support from both existing and new investors “shows the potential of our business model”, comments co-founder and CEO Pascal Winnen in the press release. “With our fast-growing team of highly qualified healthcare professionals as well as a strong network of specialized consultants, we will continue to offer our shareholders the opportunity to identify and invest in early-stage healthcare startups, with active management of the portfolio”, he adds.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.